PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|May 9, 2018
LMT Group Opens New Facility in Nanjing
Author(s)Pharmaceutical Technology Editors
A new facility will allow Fette Compacting to double its production capacity for tablet presses in Nanjing, China.
Advertisement
After having been active in China for more than ten years and steadily building its presence there, the LMT Group of companies has now opened a new factory and administration building in the Chinese city of Nanjing. This investment will enable Fette Compacting to double its production capacity for tablet presses and LMT Tools to broaden its service offering for precision tools, the group said in a May 9, 2018 press release.
The new facility is 50,000 square meters in size, and operations officially began May 8, 2018. Before the opening of the new building, Fette Compacting produced approximately 100 tablet presses a year in Nanjing, which were delivered to customers worldwide. The new facility will enable Fette Compacting China to double its production capacity.
“We are firmly maintaining our current course of internationalization. That is how we can ensure the continued availability of state-of-the-art technology and comprehensive service to all the customers that want to engage in growth markets in China and other parts of the world and increase their international competitive edge,” explained Olaf J. Müller, CEO of Fette Compacting, in the press release.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Lessons For AI Governance in Quality Systems
5